Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain by Rodríguez-Lescure, A. et al.
Vol.:(0123456789) 
Clinical and Translational Oncology (2020) 22:2253–2263 
https://doi.org/10.1007/s12094-020-02366-y
RESEARCH ARTICLE
Study of the Spanish Society of Medical Oncology (SEOM) 
on the access to oncology drugs and predictive biomarkers in Spain
A. Rodríguez‑Lescure1  · F. A. de la Peña2 · E. Aranda3 · A. Calvo4 · E. Felip5 · P. Garrido6 · R. Vera7
Received: 2 April 2020 / Accepted: 28 April 2020 / Published online: 12 June 2020 
© The Author(s) 2020
Abstract
Purpose The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to 
oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed.
Methods A questionnaire was sent to 146 hospitals in Spain to collect information on the process of approval of 11 oncology 
drugs of an unquestionable clinical benefit and five predictive biomarkers of mandatory determination for specific treatments.
Results Results highlight the still existing differences in the access of oncology drugs, as well as the newly identified dif-
ferences in the access to predictive biomarkers between Autonomous Communities (AACC) in Spain, as well as between 
different hospitals within the same Autonomous Community.
Conclusions
The SEOM considers it necessary to reduce the differences identified, increase homogeneity, and improve conditions of 
access to oncology drugs and biomarkers, and makes proposals to address these issues.
Keywords Oncology · Drug · Biomarker · Equity · Access · Barriers · Spain
Introduction
Cancer is a primary health problem due to its high incidence, 
prevalence, and mortality rates. Worldwide in 2018, 18.1 
million new cases cancer were identified and a total of 9.5 
million cancer-associated deaths were registered. In the next 
20 years, the incidence of cancer is predicted to increase by 
approximately 64% and to reach an estimate of 29.5 million 
new cases in 2040 [1].
In Spain, an estimated total of 227,234 new cancer cases 
were detected in 2019 [1], being the second leading cause of 
mortality in the overall population following cardiovascular 
disease, and the leading overall cause in the male popula-
tion [2].
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Nevertheless, the incidence and mortality trends in some 
cancers are starting to level off, with some types of cancers 
even beginning to show decreasing rates. This suggests an 
increase in the efficacy of new therapeutic approaches as 
well as preventative policies, both at primary and second-
ary levels [2]. In the past years, cancer survival rates have 
increased steadily in Europe, especially in some cancer 
types. In Spain, survival rates are on average 53% at 5 years, 
which is comparable to those of similar countries [3–5].
One of the main developments in the treatment of patients 
with cancer is the possibility of making therapeutic deci-
sions based on the genomic and molecular characteristics of 
each patient’s tumor. This approach is known as precision 
medicine and it allows patients to receive personalized treat-
ments, with a greater efficacy and a lower toxicity than the 
conventional treatments [6, 7].
Advances in precision medicine go hand in hand with the 
identification and determination of new biomarkers. Never-
theless, many biomarkers are still not available in day-to-day 
clinical practice due to the numerous barriers and threats 
that limit their accessibility [6, 7].
An study on access to novel drugs for NSCLC carried out 
in Central and Southeastern Europe (CEE) concluded that 
the access to novel drugs was suboptimal in CEE countries 
and that availability of drugs was not in accordance with 
their value scores, like the ESMO Magnitude of Clinical 
Benefit Scale [8].
In Spain, after EU authorization, oncologic drugs must 
first be approved by the Spanish Agency of Medicines and 
Medical Products (AEMPS) and, after that, the Therapeutic 
Positioning Report (IPT) is issued. This report serves as a 
reference for any action related to the acquisition and pro-
motion of the rational use of the drug. The Inter-Ministerial 
Commission for the Pricing of Medicines (CIPM) is then 
responsable for establishing the Pricing and Reimbursement 
(PR) within the Spanish Public Health System (SNS) [9, 10]. 
Afterwards, Autonomous Communities (AACC) will cover 
the expense of the drugs as part of their regional budgets.
In this context, following the results obtained from the 
2015 study on the access of pharmaceutical drugs in Spain, 
the Spanish Society of Medical Oncology (SEOM) has car-
ried out the present study to evaluate and follow up, 4 years 
later, the access conditions to oncology drugs in real clinical 
practice throughout the Spanish territory. Furthermore, for 
the first time, the access conditions in clinical practice to 
predictive biomarkers mandatory by Data Sheet as a means 
of selecting patients for some specific oncology drugs have 
also been analyzed.
The aim of this study is to identify the different decision-
making mechanisms involved in the approval and access to 
oncology drugs and predictive biomarkers in clinical prac-
tice in Spain, analyse the availability of approved drugs and 
predictive biomarkers, as well as compare, where possible, 
how the situation has changed since 2015, and make new 
proposals on ways of tackling the barriers and inequalities 
identified.
Materials and methods
An electronic questionnaire was distributed via email to the 
Medical Oncology Services of 146 hospitals in Spain, cov-
ering all 17 AACC and the Autonomous City of Ceuta. It 
was elaborated by a group of medical oncologists belonging 
to the SEOM, who also acted as the Panel of Experts (PE) 
and are the authors of this article. They took part in work 
meetings throughout the project to monitor and evaluate 
results, identify areas of improvement, and make subsequent 
proposals.
The PE decided the drugs and biomarkers included in this 
study based on the following criteria: (1) unquestionable 
clinical benefit, (2) funding granted in Spain between 2016 
and 2018, (3) drugs whose access issues could have a great 
effect on the adequate treatment of patients, and (4) could 
be representative of current access conditions in Spain. As 
a result, the PE selected approved indications for 11 drugs 
and five predictive biomarkers mandatory for the prescrip-
tion of specific oncology drugs under Data Sheet require-
ments, to address the following conditions: non-microcytic 
lung cancer (drugs: pembrolizumab, atezolizumab, and 
nivolumab; biomarkers: PDL-1, ALK, and ROS-1), breast 
cancer (drugs: ribociclib and palbociclib), melanoma (drugs: 
dabrafenib + trametinib and cobimetinib + vemurafenib; bio-
marker: BRAF), and ovarian cancer (drug: olaparib; bio-
marker: BRCA1/BRCA2) (Tables 1 and 2).
The questionnaire requested descriptive data of each 
centre and information on the commissions and decision-
making bodies involved in the access. For each drug/indi-
cation, information requested included dates of application 
and approval/denial for use; approved usage conditions and 
any barriers or limitations. For each biomarker, information 
requested included availability of procedures for requesting 
their determination; in house or outsourced determination 
and response times; usage criteria; funding of the determina-
tion in clinical practice; management and registering plat-
forms, and any barriers or limitations identified. The detail 
of the questions included is shown in Annexes 1, 2, and 3.
The time taken from the EC authorization and from the 
fixing of PR conditions in Spain until the approval of each 
drug /indication for its prescription in each individual hos-
pital was measured. The minimum, maximum, and median 
times were also calculated.
A literature review was carried out on all relevant content 
published in the web pages of the EC, EMA, General Direc-
torate of Pharmacy and Medicinal Products of the Spanish 
Ministry of Health, the AEMPS, regional health services as 
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well as the Official Gazettes of each Autonomous Commu-
nity, regarding the approval and use of biomarkers, as well 
as the access to oncology drugs.
This study started in December 2018 and ended in May 
2019.
Results
The questionnaire was completed by 84 hospitals (58% of 
the centres contacted). Of these, 80 are public hospitals and 
four are private hospitals, one of these being an associated 
private centre. The participating centres represent all 17 
AACC as well as the Autonomous City of Ceuta. Accord-
ing to the responses, 62% of the centres are of level 3 com-
plexity, 29% are of level 2 complexity, and 9% are of level 
1 complexity; 56% of the participant centres correspond to 
areas of over 300,000 inhabitants, 22% of areas between 
200,000 and 300,000 inhabitants, and 22% to areas below 
200,000 inhabitants.
Oncology drugs
Commissions and decision‑making bodies 
that affect the access
According to the responses, in 51% of cases, decisions 
regarding the access of the drugs are taken at hospital/health 
Area; in 42% of cases, decisions are made at Autonomous 
Community level; and in 5% of cases, decisions are made at 
a combination of levels. Results show there are clear vari-
ations between AACC. In Asturias, Baleares, Cantabria, 
C. Valenciana, Galicia, La Rioja, Navarra, and País Vasco, 
decisions are always made at Autonomous Community level; 
whereas in Castilla La Mancha and Madrid, decisions are 
Table 1  Description of the drugs and indications analysed in this study
Lung cancer Pembrolizumab 1. Monotherapy for the first-line treatment of metastatic Non-Small Cell Lung Carcinoma 
(NSCLC) in adults with tumours that express PD-L1 with a tumour maker proportion 
(TMP) ≥ 50% without positive tumour mutations o the EGFR or ALK genes
2. Monotherapy for the treatment of locally advanced or metastatic NSCLC in adults with 
tumours that express PD-L1 with a TPS ≥ 1% and that have received at least one previous 
chemotherapy treatment
Atezolizumab Monotherapy for the treatment of adult patients with locally advanced or metastatic Non-Small 
Cell Lung Carcinoma (NSCLC) that have received prior treatment with chemotherapy
Nivolumab Monotherapy for the treatment of adult patients with locally advanced or metastatic Non-Small 
Cell Lung Carcinoma (NSCLC) that have received prior treatment with chemotherapy
Breast cancer Ribociclib In combination with an aromatase inhibitor as an initial hormonal treatment of post-menopausal 
women with locally advanced or metastatic breast cancer, positive for the Hormonal Receptor 
(HR), and negative for the Human Epidermal Growth Factor 2 (HER2)
Palbociclib Treatment of metastatic or locally advanced Hormonal Receptor (HR) positive and Human 
Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer
Melanoma Dabrafenib y Trametinib Trametinib in combination dabrafenib for the treatment of adult patients with non-resectable or 
metastatic melanoma with a BRAF 600 mutation
Cobimetinib y Vemurafenib Cobimetinib in combination with vemurafenib for the treatment of adult patients with non-
resectable or metastatic melanoma with a BRAF V600 mutation
Ovarian cancer OLAPARIB Monotherapy for the treatment of adult patients with BRCA-mutated (germline or somatic) 
advanced high-grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal 
cancer, in relapse and sensitive to platinum, following first-line platinum-based chemotherapy 
(complete or partial response)
Table 2  Description of the biomarkers and indications analysed in this study
Lung cancer PD-L1 Expression of the PD-L1 predictive biomarker in response to the treatment of Non-
Small-Cell Lung Carcinoma (NSCLC)
ALK Rearrangement of ALK as a predictive biomarker in response to the treatment of NSCLC
ROS-1 Translocation of ROS-1 as a predictive biomarker in response to the treatment of NSCLC
Melanoma BRAF Mutation of BRAF as a predictive biomarker in response to the treatment of Melanoma
Ovarian cancer BRCA1/BCRA2 Mutation in the BRCA1/BRCA2 genes as predictive biomarkers in response to the treat-
ment of Ovarian Cancer
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always made at a hospital/health Area level. In the remaining 
AACC, responses obtained vary between hospitals.
No information was provided on the commissions in 58% 
of the answers, either because it is not publically available 
(31%) or because it is unknown (27%).
In cases where participants have information about the 
decision-making commission, they have indicated that at 
least one medical oncologist participates in it.
Conditions for the use and the need for additional 
approvals
A total of 60% of the responses indicate that, despite having 
been authorised by the AEMPS and having fixed PR condi-
tions, the use of the drugs requires an additional authoriza-
tion by the Hospital´s Pharmacotherapy Commission (HPC).
A total of 20% of responses indicate that at least one of 
the drugs/indications included in this study had not been 
approved (15%) or were pending approval (5%). It must be 
noted that this questionnaire was carried out during the first 
4 months of 2019 and that the drugs/indications included in 
the study were designated PR conditions between January 
2016 and April 2018.
There are differences in the responses obtained regarding 
the criteria which govern the use of the drugs. These criteria 
are specified by, amongst others, regional reports, hospital 
reports developed by the HPC, and positioning reports of 
the SEOM. Furthermore, the criteria established for their 
use are not always the same as those established for their 
commercialization in Spain.
Analysis of authorization times for the approval 
of prescriptions (Table 3)
According to the responses, the time taken from the designa-
tion of PR until approval for prescription within the differ-
ent hospitals shows great variability, ranging between 0 and 
36 months. For palbociclib, the median was of 5 months, 
(ranging from 1 to 12 months); 5.75 months for ribociclib 
(2–13 months); 6.5 months for atezolizumab in NSCLC 
(1–16 months); 7 months for cobimetinib + vemurafenib 
(0 to 24 months); 10 months for dabrafenib + trametinib 
(5–30  months); 10.5  months for pembrolizumab 1st L 
NSCLC (1 to 18 months); 11 months for pembrolizumab 
in 2ndL NSCLC (1–26 months); 13 months for olaparib 
(1–35 months); and 17 months for nivolumab in NSCLC 
(1 to 36 months).
Timescales from the EC authorization until the 
approval for prescription at different hospitals ascend up 
to 48 months (olaparib), with medians ranging between 
87.5 months (ribociclib between 5 and 18 months) and 
26 months (olaparib between 14 and 18 months). For 
the remaining drugs/indications, median timescales 
in ascending order are the following: 13  months for 
atezolizumab (7–23 months); 16.5 months for palboci-
clib (12–24 months); 17 months for pembrolizumab 1st 
NSCLC (7–25 months), 17 months for pembrolizumab 
2nd NSCLC (7–32 months), and 21 months for nivolumab 
(5–40 months).
Table 3 shows the median time from the designation of 
the PR until the authorization at each Autonomous Com-
munity, as well as the minimum, maximum, and global 
median for each of the drugs/indication. The time taken 
from the EC authorization until PR is also shown.
Barriers to the access of oncology drugs
In 43% of the centres, barriers to the access and use have 
been detected for at least one of the drugs analyzed. These 
barriers primarily consist of: delays and slowness of the 
approval process; requirement of a supporting report for 
each patient, which means additional delays and can result 
in the denial of the request; use criteria more restrictive 
than those established for the drug commercialization in 
Spain; selection of other drugs with the same indication 
and a different mechanism of action for use in the cen-
tre; non-approval or a pending approval of the drug in the 
centre.
Biomarkers
Commissions and decision‑making bodies
Responses to the questionnaire and the bibliographic review 
show that there are no standardized criteria for the imple-
mentation of biomarkers in clinical practice in Spain.
According to the answers, in most AACC, there are great 
variations between hospitals regarding how and where the 
decisions for the approval of biomarkers are made.
In 84% of centres, there is no established commission or 
decision-making body responsible for making decisions on 
the access of predictive biomarkers or there is no informa-
tion in this regard.
In the majority of centres that do have a decision-mak-
ing body, such decisions are made in one of the following: 
Tumour or Molecular Pathology Committee; Tumours or 
Genetic Committee.
Some participants have indicated that, at the end date of 
the study (May 2019), some of the AACC were implement-
ing, or starting to work on the implementation of mecha-
nisms for the management of biomarkers determination in 
clinical practice and on their possible inclusion in the port-
folio of services offered by the region.
2257Clinical and Translational Oncology (2020) 22:2253–2263 
1 3
Ta
bl
e 
3 
 T
im
e 
ta
ke
n 
in
 m
on
th
s f
ro
m
 th
e 
PR
 fi
xa
tio
n 
of
 a
n 
in
di
ca
tio
n 
un
til
 th
e 
ap
pr
ov
al
 fo
r i
ts
 u
se
A
ut
on
om
ou
s c
om
m
un
ity
Pe
m
br
ol
iz
um
ab
 1
L
Pe
m
br
ol
iz
um
ab
 2
L
A
te
zo
liz
um
ab
N
iv
ol
um
ab
R
ib
oc
ic
lib
M
ed
M
in
M
ax
N
M
ed
M
in
M
ax
N
M
ed
M
in
M
ax
N
M
ed
M
in
M
ax
N
M
ed
M
in
M
ax
N
A
nd
al
uc
ía
12
8
16
12
11
1
14
11
4
1
8
12
20
3
36
12
6.
5
2
13
10
A
ra
gó
n
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
4
4
4
–
A
stu
ria
s
10
10
10
1
–
–
–
–
0
0
0
1
–
–
–
–
–
–
–
–
B
al
ea
re
s
10
.5
6
15
2
17
.5
13
22
2
7
7
7
2
24
24
24
2
5
5
5
2
C
. d
e 
M
ad
rid
9
1
14
9
13
1
18
9
7
3
8
9
20
.5
1
29
9
4
3
12
7
C
. L
a 
M
an
ch
a
15
15
15
5
22
22
26
6
7
7
7
6
12
10
13
6
–
–
–
5
C
. V
al
en
ci
an
a
13
13
13
6
9.
5
3
16
6
5
5
5
6
8
4
12
6
3,
5
2
5
6
C
an
ar
ia
s
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
C
an
ta
br
ia
0
0
0
1
–
–
–
–
–
–
–
–
19
19
19
1
–
–
–
C
as
til
la
 y
 L
eó
n
6
6
6
4
10
10
10
4
8
8
8
4
14
13
17
5
–
–
–
–
C
at
al
uñ
a
8
5
9
11
13
.5
0
16
11
2
0
16
9
15
2
26
10
7
4
9
10
C
eu
ta
13
13
13
1
–
–
–
–
–
–
–
–
33
33
33
1
–
–
–
Ex
tre
m
ad
ur
a
–
–
–
–
––
–
–
–
–
–
–
–
1
1
1
1
–
–
–
–
G
al
ic
ia
18
18
18
4
–
–
–
–
3
3
3
4
–
–
–
–
–
–
–
–
La
 R
io
ja
0
0
0
1
–
–
–
–
6
6
6
1
–
–
–
–
–
–
–
–
M
ur
ci
a
15
15
15
2
1
1
1
2
4
4
4
2
13
10
16
2
7
7
7
2
N
av
ar
ra
9
9
9
1
5
5
5
1
7
7
7
1
–
–
–
–
–
–
–
–
Pa
ís
 V
as
co
3.
5
3
4
3
11
11
11
3
8
8
8
2
23
23
23
2
6.
5
6
7
3
G
lo
ba
l M
ed
ia
n 
(m
on
th
s)
10
11
6
17
6
Pe
m
br
ol
iz
um
ab
 1
L
Pe
m
br
ol
iz
um
ab
 2
L
A
te
zo
liz
um
ab
N
iv
ol
um
ab
R
ib
oc
ic
lib
D
at
e 
of
 a
pp
ro
va
l b
y 
th
e 
EC
27
/0
1/
20
17
29
/0
7/
20
16
21
/0
9/
20
17
28
/1
0/
20
15
22
/0
8/
20
17
D
at
e 
of
 P
R
 fi
xi
ng
 fo
r t
he
 in
di
ca
tio
n
01
/0
8/
20
17
01
/0
1/
20
17
01
/0
4/
20
18
01
/0
2/
20
16
01
/1
1/
20
17
A
ut
on
om
ou
s c
om
m
un
ity
Pa
lb
oc
ili
b
D
ab
ra
fe
ni
b 
an
d 
tra
m
et
in
ib
C
ob
im
et
in
ib
 a
nd
 v
em
ur
af
en
ib
O
la
pa
rib
M
ed
M
in
M
ax
N
M
ed
M
in
M
ax
N
M
ed
M
in
M
ax
N
M
ed
M
in
M
ax
N
A
nd
al
uc
ía
7.
5
5
11
11
9
5
22
11
6
0
16
11
28
14
35
10
A
ra
gó
n
4
4
4
3
–
–
–
–
–
–
–
–
–
–
–
3
A
stu
ria
s
0
0
0
1
11
11
11
1
5
5
5
1
13
13
13
1
B
al
ea
re
s
5
5
5
2
–
–
–
–
–
–
–
–
29
29
29
2
C
. d
e 
M
ad
rid
4
3
10
10
19
14
25
8
16
16
19
7
13
1
33
6
C
. L
a 
M
an
ch
a
11
1
12
6
9
9
9
5
7
3
11
5
–
–
–
4
C
. V
al
en
ci
an
a
2
2
2
7
14
14
14
5
12
12
12
5
0
0
0
6
C
an
ar
ia
s
–
–
–
–
10
10
10
1
3
3
3
1
32
32
32
1
C
an
ta
br
ia
–
–
–
–
21
21
21
1
21
21
21
1
–
–
–
1
C
as
til
la
 y
 L
eó
n
7
7
7
4
18
18
18
4
12
12
12
5
20
20
20
3
2258 Clinical and Translational Oncology (2020) 22:2253–2263
1 3
Access to biomarkers
In 96% of the participating centres, it is possible to request 
the determination of the predictive biomarkers included in 
this study (93–98% depending on the biomarker).
There is great diversity about the criteria followed for 
the access. In 32% of the responses, the criteria estab-
lished in the drug´s Data Sheet are followed; in 26%, the 
consensus reports of the SEOM-SEAP (Spanish Society 
for Pathologic Anatomy) or the clinical guidelines are fol-
lowed; in 20%, the guidelines of the IPTs are followed; 
and 12% follow reports of the corresponding Autonomous 
Community.
The determination of the biomarkers included in this 
study is outsourced to other centres in the following vary-
ing percentages: 29% for PDL-1, 36% for BRAF, 37% for 
ALK, 47% for ROS-1, and 63% for BRCA1/BRCA2. In the 
remaining cases, determinations are carried out in house.
Biomarkers funding
Responses regarding the source of funding for each bio-
marker vary between AACC, as well as between hospitals 
within a given Autonomous Community and between differ-
ent biomarkers within a given hospital.
In more than 50% of the participating centres, pharma-
ceutical companies are the source funding for the determina-
tion for clinical purposes of at least one of the biomarkers 
included in the study. In the remaining centers, the source 
of funding, public or private, cannot be determined due to 
the type of answers obtained.
A vast majority of the centres indicate that they do not 
employ any computer platform to manage and register the 
determination of predictive biomarkers. These kinds of reg-
istries are used when determinations are outsourced to other 
centres and are funded by pharmaceutical companies.
Time taken from the request until results
The average estimated time taken from the request of the 
determination for the predictive biomarkers until the attain-
ment of results varies between biomarkers, AACC and 
hospitals.
Median times vary from 7 days in PD-L1 in advanced 
NSCLC (from 2 to 21 days) to 29 days for BRCA1/BRCA2 
in advanced ovarian cancer (from 1 to 240 days). The median 
time for BRAF in metastatic melanoma is 8 days (from 1 to 
31 days); whilst in ALK and ROS1 in advanced NSCLC is 
of 10 days (from 2 to 30 days).
In centres which outsource these determinations, the time 
taken until obtaining a response is notably greater than in M
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those where the determination is carried out in house. In 
some cases, these differences can be of up to 90 days.
Barriers and limitations to the determination 
of the biomarkers
Amongst the primary barriers and/or limitations to the 
access to the biomarkers included in this study, partici-
pants have stated: the lack of standardized authorization 
procedures and of clear decision-making mechanisms; the 
dependency on the pharmaceutical industry for funding 
and, on occasions, for the designation of reference centres; 
in some cases, a lack of access to the determination; the 
time until the attainment of results, which is, in many cases, 
related to the outsourcing of the determination. In private 
hospitals, the primary barrier is the lack of coverage by pri-
vate insurance companies.
Discussion
The SEOM, from its commitment towards excellence in the 
care of cancer patients, carried out an initial study in 2015 
to identify the difficulties and differences in the access to 
oncology drugs between hospitals and AACC in Spain [11]. 
With this present study, SEOM wanted to analyse the cur-
rent situation, 4 years later, as well as to include in the study 
an analysis of the access to predictive biomarkers, essential 
tools for precision medicine. In fact, SEOM, together with 
the Spanish Society for Pathological Anatomy (SEAP) and 
the Spanish Society for Hospital Pharmacists (SEFH), has 
defended the need to develop a National Precision Medicine 
Strategy [12].
The SEOM acknowledges of the existing need for a 
health system planning based both on the quality of care 
as on equal access and still considers it a priority to iden-
tify inequalities and issue proposals for improvement with 
the aim of guaranteeing the accessibility of pharmaceutical 
drugs and biomarkers in equitable conditions throughout the 
national territory, without affecting the measures taken by 
AACC to rationalize use of drugs and health products, as 
established in the modification of Article 88.1 of December 
2014 of Law 29/2006 on Guaranties and Rational Use of 
Drugs and Health Products.
The results show that there are significant differences 
between AACC regarding the scope of which decisions 
relevant to drug accessibility are made. Nevertheless, this 
analysis shows a tendency towards a greater centralization 
of decisions at an autonomic level. The responses indicate 
that in 51% of cases, decisions are made at a hospital/health 
área level (65.3% of cases in 2015), and that in 42% of cases, 
decisions are made at a regional level (27.8% of cases in 
2015). In 58% of all responses, the participants indicate that 
the composition of commissions and other decision-making 
bodies is either not publically accessible or that there is no 
information available in this regard. When this information 
is available, participants indicate that such commissions 
include at least one medical oncologist, while 9.7% of hos-
pitals indicated that no medical oncologist formed part of 
them in the study carried out in 2015.
The period to access to drugs of unquestionable therapeu-
tic value is excessively long and, above all, there are signifi-
cant differences at a regional level, and even at a hospital 
level within a given region. Without a doubt, this is a source 
of significant inequalities in the health system. Furthermore, 
43% of the participant oncologists identify access barriers to 
the use of, at least, one of the drugs analyzed. In the study 
carried out in 2015, 37.8% of participants identified barriers 
or limitations for the access to the oncology drugs analyzed.
With regards to the access of biomarkers, in Spain, there 
is neither standardized procedure nor regulatory frame-
work for the evaluation, implementation, and funding of 
biomarkers that predict the efficacy of specific oncology 
drugs in a given patient. These biomarkers are not included 
in the national portfolio of health services and, therefore, 
are authorised at regional or hospital levels following very 
different criteria and with varying approval timeframes. In 
fact, 84% of the centres included in this study do not have a 
commission or decision-making body responsible for man-
aging the access of predictive biomarkers, or at least the 
participants have no information in this regard.
Other relevant areas of inequality include the funding of 
predictive biomarker determinations and the selection of 
hospital centres where such determinations are carried out. 
This study shows that pharmaceutical companies play a sig-
nificant role in the funding, and, thus, in the organization of 
resources and the access to the biomarkers/indications that 
have been analyzed.
Concerning response times, the estimated time from the 
request for the determination of the biomarkers/indications 
until the availability of a result varies significantly between 
biomarkers, AACC, and hospitals. The time taken is nota-
bly greater in centres that outsource the determination than 
where the determination is carried out in house.
The differences in the access to oncology drugs and pre-
dictive biomarkers could impact on the health outcomes, 
even though this impact has not been measured in this study 
due to the limitations in its scope.
Given this situation, the SEOM expresses its concern 
regarding the variability in the access to oncology drugs as 
well as to biomarkers which are necessary for the correct 
selection of certain treatments that have an unquestionable 
clinical benefit, in the different AACC and in different hos-
pital centres within the same Autonomous Community.
The SEOM, therefore, considers it necessary to imple-
ment initiatives with the following objectives:
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1. Include biomarkers in the portfolio of common services 
of the Spanish National Health System (SNS).
2. Develop a standardized procedure and a regulatory 
framework for the implementation and funding of the 
biomarkers.
3. Determine which biomarkers should be carried out in 
house and which must be carried out in reference cen-
tres.
4. Reduce the identified differences and increase homoge-
neity in the access to drugs in Spain, demanding that the 
same conditions apply throughout the Spanish territory 
and that the competent decision-making bodies approve 
these common conditions.
  To achieve this, there is a need to:
• Ensure total transparency in the composition and 
decisions of commissions and other decision-making 
bodies
• Eliminate barriers at a regional level (AACC) and 
hospital level
5. Reduce existing delays between the date of approval of 
drugs for their commercialization in Spain and the date 
of approval for their prescription to patients.
  To achieve this, there is a need to:
• Limit the time taken for the inclusion of new drugs in 
the AACC following the authorization by the Span-
ish Ministry of Health.
• Eliminate bureaucratic procedures, such as addi-
tional supporting reports following the attainment of 
published IPTs as well as Scientific Society reports 
prepared by experts.
Measure health outcomes to understand the real impact of 
introducing a new drug, using the tools designed in collabo-
ration with the General Directorate of Basic Portfolio of Ser-
vices of the Spanish National Health System and Pharmacy, 
and that these be used in every Autonomous Community 
with the same criteria.
Conclusions
This study shows that there are still variations in the access 
of drugs as well as of biomarkers that predict the efficacy of 
different oncology drugs between different AACC as well as 
at a hospital level within a given Autonomous Community.
In addition to the significant differences in the deci-
sion-making process, access times for these drugs are still 
worrisome, not only due to its length, but also due to the 
notable differences between AACC and between hospitals 
for a given drug. Additionally, the fact that biomarkers are 
not included in the basic portfolio of services of the SNS 
means that biomarkers are introduced differently in the 
different AACC and in different hospitals.
This situation could directly affect patients, whose 
access to certain drugs and predictive biomarkers depends 
on the region and on the centre where they are being 
treated.
For this reason, the SEOM expresses its concern and con-
siders it necessary to implement initiatives to (a) reduce the 
detected differences to ensure equity in drug access, regard-
less of the patients´ place of residence, and reduce delays in 
the time taken from the EC authorization until use in hospi-
tals, (b) include biomarkers in the basic portfolio of drugs 
and services of the SNS, and (c) measure health outcomes 
to understand the real impact of introducing new treatments 
and biomarkers.
The SEOM would like to offer itself as a collaborative 
partner for the Spanish health authorities in promoting ini-
tiatives aimed at ensuring equity and the optimal access of 
oncology drugs and biomarkers, regardless of a patients´ 
place of residence.
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Appendix
Appendix 1. Descriptive data requested for each 
centre
1. Select your province (MANDATORY)
2. Select the level of your hospital
3. Select the number of inhabitants of your reference popu-
lation
4. Select the scope of influence of the Pharmacotherapy 
Commission where binding decisions regarding the 
drug access in your centre are made: (Please select one 
option)
• ☐ Hospital
• ☐ Group of hospitals
• ☐ Health area
• ☐ Province
• ☐ Autonomous Community
• ☐ Unknown
  Do you know the number of members that form the 
previously mentioned Commission?
• ☐ Yes
• ☐ No
  If the chosen answer is “YES”, please indicate the 
following:
  Number of members in the previously mentioned 
Commission:
  Number of medical oncologists that take part in the 
commission:
  Is this information publically available?
• ☐ Yes
• ☐ No ☐Unknown
5. Are there any electronic prescription mechanisms avail-
able? Please indicate.
6. Select the level that decisions regarding the determina-
tion of predictive biomarkers of response to treatment 
with oncology drugs are made:
• ☐ Hospital
• ☐ Group of hospitals
• ☐ Health area
• ☐ Province
• ☐ Autonomous Community
• ☐ Unknown
• ☐ No binding decisions are made at any level
7. In your centre, is there a Commission or any other 
decision-making body responsible for making deci-
sions regarding the access to predictive biomarkers of 
response to treatment with oncology drugs?
• ☐ Yes (please indicate which)
• ☐ No ☐ Unknown
  If the selected answer is “YES”, is the information 
on its existence and means of operation publically avail-
able?
8. Additional comments
Appendix 2. Requested data on the access 
of the drugs and indications analysed (for each 
drug/indication)
1. Has the request for the use of the drug in your centre 
been presented to the Pharmacotherapy Commission?
• ☐ Yes
• ☐ No
• ☐ No, approval is granted by the regional Commis-
sion where presenting the drug is not necessary
• ☐ Unknown
  If the answer is “No”, what was the primary 
motive for not presenting a request?
• ☐ Unofficial negative response
• ☐ Excessive delay
• ☐ Excessive burocracy
• ☐ It does not affect my prescription
2. Has the drug been approved for clinical use for the given 
indication in your hospital?
• Yes ☐
• No ☐
• Pending evaluation ☐ (indicate date)
  If the chosen answer is “YES”, please indicate the 
date of approval (month/year)
  If the chosen answer is “NO”, have patients been 
derived to other centres that have access to the drug?
  If the chosen answer is “NO”, are there any alter-
native prescription mechanisms in place that grant 
access to the drug?
  Yes ☐ (Please indicate) No ☐
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3. If the use of the drug has been approved in the hospital 
for the given indication, is its use governed by/depend-
ent on the criteria established in…? Please select one or 
more of the following options:
• ☐ Data Sheet (Ficha Técnica, FT)
• ☐ It has been approved under the same conditions as 
the Data Sheet (FT)
• ☐ It has been approved under more restrictive condi-
tions than those of the Data sheet (FT)
• ☐ It has been approved under less restrictive condi-
tions than those of the Data Sheet (FT)
• ☐ Therapeutic Positioning Report (Informe de Posi-
cionamiento Terapéutico, IPT)
• ☐ It has been approved under the same conditions as 
the Therapeutic Positioning Report (IPT)
• ☐ It has been approved under more restrictive con-
ditions than those of the Therapeutic Positioning 
Report (IPT)
• ☐ It has been approved under less restrictive con-
ditions than those of the Therapeutic Positioning 
Report (IPT)
• ☐ Regional Report (Autonomous Community)
• ☐ Hospital Report prepared by the Pharmacotherapy 
Commission
• ☐ SEOM Evaluation Report
• ☐ Genesis Evaluation Report
• ☐ The drug is not available in the centre
• ☐ Others Please specify
4. Can you identify any barriers / limitations to the access 
of the drug for the given indication in your center?:
  No ☐ Yes ☐
  If the chosen answer is yes, please select one or more 
of the following options regarding the barriers to access 
the drug in your centre:
• ☐ The requirements established by the centre are 
more restrictive than those included in the Data 
Sheet
• ☐ Drafting of a supporting report specific to each 
patient is required
• ☐ Expenditure capping systems have been imple-
mented
• ☐ No medical oncologists take part in the Pharma-
cotherapy Commission
• ☐ Lack of hospital budget
• ☐ A different drug with the same indication but a 
lower price has been approved
• ☐ The sequence of treatments for the same indication 
are not permitted
• ☐ Other barriers to the use. Please specify which
5. Please add any other relevant comments.
Appendix 3. Requested data on the access 
to the analysed biomarkers (for each biomarker/
indication)
 1. In your centre, is it possible to request the determi-
nation of the biomarker as a predictive biomarker of 
response to the treatment of the given indication?
• ☐ Yes
• ☐ No
1.1 If the chosen answer is “YES”, since when has the 
use of the biomarker been possible (month and 
year)?
  Multiple choice:
1.2 If the chosen answer is “NO”, what is the reason for 
its inaccessibility?
   Multiple choice:
• ☐ Negative response from the decision-making bod-
ies
• ☐ Delay in the response
• ☐  Procedures for presenting the request are 
unknown/inexistent
• ☐ Other motives. Please specify which. Click here 
to type text.
 2. Is the use of the biomarker as a predictive biomarker 
of response to treatment for a different type of cancer 
included in the hospital´s portfolio of available ser-
vices?
• ☐ Yes. Please specify
• ☐ No.
 3. What are the available techniques for the determination 
of the biomarker as a predictive biomarker in response 
to the treatment of the given indication?
 4. Who is responsible for carrying out the determination 
of the biomarker as a predictive biomarker in response 
to the treatment of the given indication?
   The hospital itself ☐ Outsourced ☐
   Do other centres outsource their determinations to 
your centre?
• ☐ Yes. Please specify which centres. Click here to 
type text.
• ☐ No.
• ☐ Unknown.
  If determinations are outsourced, please specify to 
which centre
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 5. Is the use of the biomarker as a predictive biomarker in 
response to the treatment of the given indication gov-
erned by/ dependant on the criteria established in…? 
Please select one or more of the following options:
• ☐ Therapeutic Positioning Report (IPT) Please spec-
ify which drug
• ☐ Data Sheet (FT) Please specify which drug
• ☐ Regional Report (Autonomous Community)
• ☐ Hospital Report
• ☐ Clinical Guidelines / SEOM Consensus Reports
• ☐ Unknown
• ☐ The biomarker is not available in the centre
• ☐ Other Please specify
 6. Who is responsible for funding the biomarker determi-
nation for the purpose of predictive care for the indica-
tion in your hospital?
• ☐ Regional Health Services / Regional Ministries
• ☐ The Hospital
• ☐ Pharmaceutical Industry
• ☐ Research funds
• ☐ Other. Please specify
 7. Do you use any IT platform to manage and register the 
determination of a biomarker as a predictive biomarker 
in response to the treatment of a given indication?
• ☐ Yes, please specify
• ☐ No
 8. What is the average response time from the application 
for the determination until de availability of the result?
 9. Can you identify any barriers/limitations in your cen-
tre to the access of the biomarker as a predictive bio-
marker in response to the treatment of the given indica-
tion?
   Yes ☐ please specify No ☐
 10. Please add any other relevant comments.
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